– Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – In the Phase II KARDIA-3 study, presented today as a late ...
Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants with ...
Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results